Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 at Royal Bank Of Canada

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective upped by analysts at Royal Bank Of Canada from $18.00 to $19.00 in a report released on Tuesday,MarketScreener reports. The firm presently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target points to a potential downside of 17.68% from the company’s previous close.

Several other equities research analysts have also recently commented on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a research report on Thursday, March 26th. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Wedbush boosted their price target on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 26th. Finally, Barclays began coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Hold” and an average price target of $32.63.

Sarepta Therapeutics Stock Up 1.2%

Shares of NASDAQ SRPT opened at $23.08 on Tuesday. The stock has a market cap of $2.42 billion, a P/E ratio of -2.73, a P/E/G ratio of 0.36 and a beta of 0.29. The firm has a 50 day moving average price of $18.79 and a 200 day moving average price of $20.26. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $64.80.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same quarter last year, the business posted $1.90 earnings per share. Analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SRPT. AQR Capital Management LLC lifted its position in Sarepta Therapeutics by 214.2% during the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 3,671 shares during the period. Great Lakes Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at approximately $224,000. Guggenheim Capital LLC raised its position in shares of Sarepta Therapeutics by 33.5% in the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock valued at $783,000 after buying an additional 11,497 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Sarepta Therapeutics by 59.2% during the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock worth $10,731,000 after acquiring an additional 233,391 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in shares of Sarepta Therapeutics by 347.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock worth $22,370,000 after acquiring an additional 1,016,069 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.